Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced a plan for the reduction of shareholding by Shanghai Tanying Investment Partnership, a substantial shareholder holding more than 5% of the company’s shares. The reduction will involve no more than 20,533,797 shares, accounting for up to 2% of the total share capital, through block trading. This move is driven by the maturity of the fund and liquidity arrangements, and it reflects Shanghai Tanying’s long-term optimism about the company’s development.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development, production, and commercialization of innovative therapies. The company operates in the pharmaceutical industry, with a primary focus on biologics and small molecule drugs targeting cancer, autoimmune, and metabolic diseases.
Average Trading Volume: 12,377,720
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.27B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.